HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.

BACKGROUND: HER-2/neu status was determined by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) methods in more than 300 paraffin-embedded primary breast cancer samples. MATERIALS AND METHODS: HER-2/neu status was determined by FISH using the PathVysion kit (Vysis) and by IHC using either a monoclonal antibody CB11 or a cocktail of antibodies: the monoclonal TAB250 and the polyclonal pAb1. RESULTS: Of the 324 cases evaluable by IHC, 65 out of 318 (20%) and 24 out of 324 (7%) were scored as positive when using the antibody cocktail and the CB11, respectively. HER-2/neu gene amplification occured in 64 out of 324 cases (20%). Concordance of FISH and IHC was found in 285 out of 318 cases (90%) and 278 out of 324 cases (86%) using the cocktail and the CB11, respectively. CONCLUSION: The cost-effectiveness analysis revealed that the use of a sensitive IHC method followed by confirmation of positive results by FISH considerably decreased the FISH costs and may become standard practice for HER-2/neu evaluation.

Scalar glueballs: Constraints from the decays into η or η′

We study the mixing of the scalar glueball into the isosinglet mesons f0(1370), f0(1500), and f0(1710) to describe the two-body decays to pseudoscalars. We use an effective Hamiltonian and employ the two-angle mixing scheme for η and η′. In this framework, we analyze existing data and look forward to new data into η and η′ channels. For now, the f0(1710) has the largest glueball component and a sizable branching ratio into ηη′, testable at BESIII.

Reply to the comment on 'The dispersed laser induced fluorescence spectrum of gas phase C60 at 308 nm'

info:eu-repo/semantics/published